Abstract: There is a daily dosage for treating pulmonary arterial hypertension (PAH) of two discrete dosage forms each having up to 600 mg of rodatristat ethyl or up to 1200 mg of rodatristat ethyl once per day. There are methods for treating PAH in human patients in need thereof via administration of the dosage forms. There is also a method for treating PAH via daily administration of an amount of a first compound of rodatristat ethyl and an amount of a second compound selected from among ambrisentan, sildenafil, tadalafil, bosentan, treprostinil, selexipag, macitentan, and a combination of two or more thereof. The combination results in an additive or synergistic reduction in symptoms or side effects of PAH compared to the two alone with a low risk for drug-drug interaction, such with a Cmax, unbound in the bloodstream of less than 0.028 ?M. The combination can also result in neither rodatristat ethyl nor its active metabolite rodatristat substantially impacting metabolism of the second compound in the bloodstream.

Abstract: Embodiments provide methods and apparatus for fabricating blood products, such as platelet-rich plasma, containing elevated concentrations of growth factors such as platelet derived growth factor. The platelet-rich plasma can be autologous, and the concentration of growth factors (e.g., platelet derived growth factor) is elevated relative to other samples isolated from the same subject. The platelet-rich plasma can be used to promote tissue regeneration, including wound healing, joint repair, hair growth, and the like. The compositions can be combined with stem cells and used to treat disorders otherwise treated with stem cells. The growth factors present in the samples can direct the differentiation of the stem cells.

Abstract: Provided herein are compounds, compositions, and methods for modifying mucus, including modifying mucus using nitric oxide-releasing biopolymers (e.g., NO-releasing chitosan oligosaccharides). In some embodiments, a compound, composition, and/or method of the present invention modifies one or more properties of mucus to increase mucus clearance in a subject and/or prevents the growth or kills one or more pathogens present in mucus of a subject.

Abstract: Provided herein are compounds, compositions, and methods for modifying mucus, including modifying mucus using nitric oxide-releasing biopolymers (e.g., NO-releasing chitosan oligosaccharides). In some embodiments, a compound, composition, and/or method of the present invention modifies one or more properties of mucus to increase mucus clearance in a subject and/or prevents the growth or kills one or more pathogens present in mucus of a subject.